title: Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review.
abstract: OBJECTIVE
  The aim of this paper is to assess the clinical response to golimumab (GLM) in patients with non-infectious uveitis from a single centre that had previously been treated with other anti-TNF-α drugs.
  
  
  METHODS
  A retrospective chart review was carried out of patients with immune-mediated uveitis refractory to standard synthetic immunosuppressive drugs who were treated with GLM at Hospital Universitario Marqués de Valdecilla, Santander (Spain). Patients were included in this study if they had previously been treated with other anti-TNF-α drugs. A literature review of patients with immune-mediated uveitis undergoing GLM therapy was conducted.
  
  
  RESULTS
  Three patients (2 men and 1 woman) were included in this study. Two of them were refractory to other anti-TNF-α drugs. The median age of patients was 26 years (range 20-42). Uveitis was bilateral in two patients. The underlying diseases were uveitis associated with HLA-B27 and psoriasis in one case and sarcoidosis in the other two cases. Improvement of the main ocular parameters following GLM therapy was achieved in all cases. After a median follow-up of 3 (range 1-9) months using GLM therapy, none of the patients had experienced new relapses of uveitis. None of them had side effects during treatment with this drug. A literature review disclosed that our observations were in keeping with other reports that showed good response to GLM in 13 of 16 patients with immune-mediated uveitis refractory to other biologic agents.
  
  
  CONCLUSIONS
  Although the follow-up was too short in our series, GLM could be an effective and safe therapy for the management of patients with uveitis previously treated with other anti-TNF-α drugs.
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain. fiorelfa@hotmail.com.
authors.forename: Vanesa
authors.initials: V
authors.lastname: Calvo-Río
authors.forename: David
authors.initials: D
authors.lastname: de la Hera
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.forename: Emma
authors.initials: E
authors.lastname: Beltrán-Catalán
authors.forename: Javier
authors.initials: J
authors.lastname: Loricera
authors.forename: Joaquín
authors.initials: J
authors.lastname: Cañal
authors.forename: Juan
authors.initials: J
authors.lastname: Ventosa
authors.forename: José M
authors.initials: JM
authors.lastname: Cifrián
authors.forename: Francisco
authors.initials: F
authors.lastname: Ortiz-Sanjuán
authors.forename: Javier
authors.initials: J
authors.lastname: Rueda-Gotor
authors.forename: M Carmen
authors.initials: MC
authors.lastname: González-Vela
authors.forename: Marcos
authors.initials: M
authors.lastname: González-López
authors.forename: Miguel A
authors.initials: MA
authors.lastname: González-Gay
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004351:Drug Resistance; D057915:Drug Substitution; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab